Soligenix Competitors

Calithera Biosciences (NASDAQ:CALA) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Earnings and Valuation

This table compares Calithera Biosciences and Soligenix's revenue, earnings per share and valuation.

Soligenix has lower revenue, but higher earnings than Calithera Biosciences. Soligenix is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Calithera Biosciences and Soligenix, as provided by MarketBeat.com.

Calithera Biosciences presently has a consensus price target of $5.3333, suggesting a potential upside of 82.65%. Soligenix has a consensus price target of $3.4375, suggesting a potential upside of 108.33%. Given Soligenix's higher possible upside, analysts plainly believe Soligenix is more favorable than Calithera Biosciences.

Volatility and Risk

Calithera Biosciences has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Calithera Biosciences and Soligenix's net margins, return on equity and return on assets.

Institutional & Insider Ownership

74.0% of Calithera Biosciences shares are owned by institutional investors. Comparatively, 9.4% of Soligenix shares are owned by institutional investors. 11.9% of Calithera Biosciences shares are owned by company insiders. Comparatively, 3.1% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Calithera Biosciences beats Soligenix on 10 of the 14 factors compared between the two stocks.

Concert Pharmaceuticals (NASDAQ:CNCE) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Concert Pharmaceuticals and Soligenix's top-line revenue, earnings per share (EPS) and valuation.

Soligenix has higher revenue and earnings than Concert Pharmaceuticals. Soligenix is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Concert Pharmaceuticals and Soligenix, as provided by MarketBeat.

Concert Pharmaceuticals presently has a consensus price target of $21.00, suggesting a potential upside of 213.90%. Soligenix has a consensus price target of $3.4375, suggesting a potential upside of 108.33%. Given Concert Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Concert Pharmaceuticals is more favorable than Soligenix.

Risk & Volatility

Concert Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Profitability

This table compares Concert Pharmaceuticals and Soligenix's net margins, return on equity and return on assets.

Institutional and Insider Ownership

69.7% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Soligenix shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Concert Pharmaceuticals beats Soligenix on 9 of the 14 factors compared between the two stocks.

Soligenix (NASDAQ:SNGX) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Soligenix and OptiNose, as reported by MarketBeat.com.

Soligenix currently has a consensus target price of $3.4375, indicating a potential upside of 108.33%. OptiNose has a consensus target price of $19.00, indicating a potential upside of 389.69%. Given OptiNose's stronger consensus rating and higher probable upside, analysts clearly believe OptiNose is more favorable than Soligenix.

Profitability

This table compares Soligenix and OptiNose's net margins, return on equity and return on assets.

Institutional & Insider Ownership

9.4% of Soligenix shares are owned by institutional investors. Comparatively, 62.9% of OptiNose shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Soligenix has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, OptiNose has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Valuation & Earnings

This table compares Soligenix and OptiNose's top-line revenue, earnings per share (EPS) and valuation.

Soligenix has higher earnings, but lower revenue than OptiNose. Soligenix is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats Soligenix on 9 of the 13 factors compared between the two stocks.

Soligenix (NASDAQ:SNGX) and Medicenna Therapeutics (NASDAQ:MDNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Soligenix and Medicenna Therapeutics' gross revenue, earnings per share and valuation.

Medicenna Therapeutics has lower revenue, but higher earnings than Soligenix. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.4% of Soligenix shares are held by institutional investors. Comparatively, 3.9% of Medicenna Therapeutics shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Soligenix and Medicenna Therapeutics, as reported by MarketBeat.

Soligenix currently has a consensus target price of $3.4375, indicating a potential upside of 108.33%. Medicenna Therapeutics has a consensus target price of $10.00, indicating a potential upside of 155.75%. Given Medicenna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Medicenna Therapeutics is more favorable than Soligenix.

Volatility and Risk

Soligenix has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Soligenix and Medicenna Therapeutics' net margins, return on equity and return on assets.

Summary

Medicenna Therapeutics beats Soligenix on 8 of the 13 factors compared between the two stocks.

scPharmaceuticals (NASDAQ:SCPH) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares scPharmaceuticals and Soligenix's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for scPharmaceuticals and Soligenix, as reported by MarketBeat.com.

scPharmaceuticals presently has a consensus price target of $12.3333, indicating a potential upside of 67.12%. Soligenix has a consensus price target of $3.4375, indicating a potential upside of 108.33%. Given Soligenix's higher probable upside, analysts plainly believe Soligenix is more favorable than scPharmaceuticals.

Valuation & Earnings

This table compares scPharmaceuticals and Soligenix's gross revenue, earnings per share and valuation.

Soligenix has higher revenue and earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

scPharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

62.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of Soligenix shares are held by institutional investors. 4.1% of scPharmaceuticals shares are held by insiders. Comparatively, 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Soligenix (NASDAQ:SNGX) and Novan (NASDAQ:NOVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Soligenix and Novan, as provided by MarketBeat.

Soligenix presently has a consensus price target of $3.4375, indicating a potential upside of 108.33%. Novan has a consensus price target of $1.50, indicating a potential upside of 5.63%. Given Soligenix's higher probable upside, analysts clearly believe Soligenix is more favorable than Novan.

Institutional and Insider Ownership

9.4% of Soligenix shares are held by institutional investors. Comparatively, 6.2% of Novan shares are held by institutional investors. 3.1% of Soligenix shares are held by company insiders. Comparatively, 3.0% of Novan shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Soligenix and Novan's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Soligenix and Novan's revenue, earnings per share (EPS) and valuation.

Soligenix has higher earnings, but lower revenue than Novan. Soligenix is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Soligenix has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Novan has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.

Summary

Soligenix beats Novan on 8 of the 14 factors compared between the two stocks.